Daily non-political popular news in brief.

New analysis shows Kadian alleviates chronic moderate-to-severe non-malignant neck pain

Data presented this week at the American Academy of Physical Medicine and Rehabilitation meeting, demonstrated that Kadian improved sleep and overall quality of life in patients with moderate-to-severe chronic neck pain who had inadequate relief on previous analgesic regimens. Kadian is an extended-release formulation of morphine sulfate.

Read more »

Keywords: analysis, shows, kadian, alleviates, chronic, moderate-to-severe, non-malignant, neck, pain, analysi, show, alleviate, moderate, severe, non, malignant

« Previous | Next »

Similar news on "New analysis shows Kadian alleviates chronic moderate-to-severe non-malignant neck pain":

1. Alpharma presents Phase 2 results of investigational abuse-deterrent opioid ALO-01
   10-15-2007 · EurekAlert!
   Alpharma Pharmaceuticals LLC, a subsidiary of Alpharma Inc., a leading global specialty pharmaceutical company, presented results from a Phase 2 study that showed ALO-01, an extended-release morphine sulfate plus sequestered naltrexone, provided similar effectiveness to KADIAN (morphine sulfate extended-release) capsules in osteoarthritis patients with moderate-to-severe chronic pain. The data were presented at the annual meeting of the American Society of Anesthesiologists in San Francisco, Calif., on Oct. 15, 2007.
   Similar news · Read more »
   
2. New findings show Enbrel significantly reduced levels of C-reactive protein
   02-01-2008 · EurekAlert!
   Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein, a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Median reduction in CRP levels was 10 times greater in the ENBREL treated group compared to the placebo treated group. These results will be presented today at the American Academy of Dermatology Scientific Meeting in San Antonio, Texas.
   Similar news · Read more »
   
3. Literature review shows spinal manipulation beneficial for neck pain
   05-02-2007 · EurekAlert!
   A new literature review finds evidence that patients with chronic neck pain reported significant improvement following chiropractic spinal manipulation.
   Similar news · Read more »
   
4. Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis
   02-02-2008 · EurekAlert!
   One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe psoriasis. According to findings presented at the Annual Meeting of the American Academy of Dermatology, 87 percent and 91 percent of patients responding to ustekinumab 45 mg or 95 mg maintenance therapy, respectively, sustained at least a 75 percent improvement in psoriasis through one year.
   Similar news · Read more »
   
5. Survey indicates people with chronic moderate to severe plaque psoriasis may be undertreated
   02-02-2007 · EurekAlert!
   The National Psoriasis Foundation and Amgen today released data, which show that nearly 40 percent of patients with chronic moderate to severe psoriasis are not currently receiving any treatment. Further, more than half of moderate to severe patients on treatment are not being treated in accordance with AAD guidelines, which state that patients diagnosed with chronic moderate to severe plaque psoriasis are candidates for phototherapy or systemic therapy, including biologic agents.
   Similar news · Read more »
   
6. Novel MS drug shows promise in 2 lethal leukemias
   08-28-2007 · EurekAlert!
   A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia. The laboratory and animal study focused on the drug, called fingolimod. Researchers said it might help patients with advanced chronic myelogenous leukemia or acute lymphocytic leukemia, and whose cancer cells show a particular genetic change called the Philadelphia chromosome.
   Similar news · Read more »
   
7. Regular marijuana use increases risk of hepatitis C-related liver damage
   01-28-2008 · EurekAlert!
   Patients with chronic hepatitis C infection should not use marijuana daily, according to a study published in Clinical Gastroenterology and Hepatology. Researchers found that HCV patients who used cannabis daily were at significantly higher risk of moderate to severe liver fibrosis, or tissue scarring. Additionally, patients with moderate to heavy alcohol use combined with regular cannabis use experienced an even greater risk of liver fibrosis.
   Similar news · Read more »
   
8. Research identifies protein that signals flowering in squash plants
   05-31-2007 · EurekAlert!
   In research published today in the Plant Cell, analysis of the phloem sap collected from daylength-induced and non-induced squash plants shows that the presence of FT-Like protein, but not FT-Like mRNA, is highly correlated with the onset of flowering. This research provides some of the most solid evidence to date that FT protein acts as a florigenic signal.
   Similar news · Read more »
   
9. REMICADE-treated patients experienced substantial improvement in psoriasis in critical body regions
   02-01-2008 · EurekAlert!
   Data from an integrated analysis of three randomized, placebo-controlled trials showed patients with moderate to severe psoriasis receiving REMICADE achieved a consistently high level of skin clearance in the head, trunk, lower and upper extremities as measured by the Psoriasis Area Severity Index. At week 10 of the analysis, 71 percent and 79 percent of patients receiving REMICADE 3 mg/kg or 5 mg/kg, respectively, achieved a at least a 75 percent improvement in psoriasis.
   Similar news · Read more »
   
10. First placebo-controlled study of cognitive impairment due to chronic Lyme disease
    10-10-2007 · EurekAlert!
    Findings from the first placebo-controlled study of chronic cognitive impairment after treated Lyme disease demonstrate that patients report moderate cognitive impairment, physical dysfunction comparable to patients with congestive heart failure, and fatigue comparable to patients with multiple sclerosis. In the study, repeated intravenous antibiotic therapy was shown to be effective in treating cognitive dysfunction and the debilitating pain, fatigue and physical dysfunction associated with this disease.
    Similar news · Read more »